Evidence map›Paper›PMID 21900886›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012

Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.

Lara A Ray, Spencer Bujarski, Pauline F Chin, Karen Miotto

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02026011 (Optimizing Naltrexone for Individuals of East Asian Descent), which is not on this map. Cited by 43 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 4 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02026011 phase2completednot on this mapstarted 2013, after this paper: background citation

Optimizing Naltrexone for Individuals of East Asian Descent

TypeinterventionalSponsorUniversity of California, Los AngelesRan2013 to 2016Enrolled87ConditionsAlcohol Use DisorderArmsNaltrexone, Placebo
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013
    Trial
  15. Trial
  16. Trial
  17. Article
  18. Review
  19. Article
  20. Pharmacogenetics of Addiction Therapy.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Lara A RayDepartment of Psychology, University of California Los Angeles, Los Angeles, CA 90095-1563, USA. lararay@psych.ucla.edu
Spencer Bujarski
Pauline F Chin
Karen Miotto
University of California, Los Angeles · USNeurobehavioral Systems · US

Funding

ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
NCRR NIH HHS M01 RR000865NCRR NIH HHS M01-RR00865NIAAA NIH HHS L30 AA017082
6 · The paper itself

Abstract

Recent clinical and laboratory studies have shown that the effects of naltrexone for alcoholism may be moderated by the Asn40Asp single-nucleotide polymorphism (SNP) of the μ-opioid receptor gene (OPRM1). Allele frequencies for this polymorphism, however, have been shown to vary substantially as a function of ethnic background, such that individuals of Asian descent are more likely to carry the minor (Asp40) allele. The objective of this study is to test the naltrexone pharmacogenetic effects of the Asn40Asp SNP in a sample of Asian Americans. This study consists of a double-blinded, randomized, placebo-controlled laboratory trial of naltrexone. Participants (n=35, 10 females; 13 Asn40Asn and 22 Asp40 carriers) were non-treatment-seeking heavy drinkers recruited from the community. After taking naltrexone or placebo, participants completed an intravenous alcohol administration session. The primary outcome measures were subjective intoxication and alcohol craving. Results suggested that Asp40 carriers experienced greater alcohol-induced sedation, subjective intoxication, and lower alcohol craving on naltrexone, as compared to placebo, and to Asn40 homozygotes. There results were maintained when controlling for ALDH2 (rs671) and ADH1B (rs1229984) markers and when examining the three levels of OPRM1 genotype, thereby supporting an OPRM1 gene dose response. These findings provide a much-needed extension of previous studies of naltrexone pharmacogenetics to individuals of Asian descent, an ethnic group more likely to express the minor allele putatively associated with improved biobehavioral and clinical response to this medication. These findings help further delineate the biobehavioral mechanisms of naltrexone and its pharmacogenetics.

Indexed as

Adrenocorticotropic HormoneAdultAlcohol DehydrogenaseAlcoholic IntoxicationAlcoholismAldehyde DehydrogenaseAldehyde Dehydrogenase, MitochondrialAllelesAsianBehavior, AddictiveDouble-Blind MethodEthanolFemaleGenotypeHumansHydrocortisoneADH1B protein, humanAdrenocorticotropic HormoneAlcohol DehydrogenaseAldehyde DehydrogenaseAldehyde Dehydrogenase, MitochondrialALDH2 protein, humanEthanolHydrocortisoneNaltrexoneNarcotic AntagonistsReceptors, Opioid, mu

Identifiers

PMID21900886
PMCPMC3242306
OpenAlexW1993516035

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.